Global Automotive Supplier Sona Comstar IPO to open on June 14, 2021, closes on June 16, 2021

Price Band of Rs. 285 – Rs. 291 per equity share of face value of Rs. 10 each (“Equity Shares”)
Bid/Offer Opening Date – Monday, June 14, 2021 and Bid/Offer Closing Date – Wednesday, June 16, 2021
Minimum Bid Lot is 51 equity shares and in multiples of 51 equity shares thereafter
The Floor Price is 28.50 times the face value of the Equity Shares and the Cap Price is 29.10 times the Face Value of the Equity Shares

Risks to Investors : • The five Book Running Lead Managers associated with the Offer have handled 23 public offers in the past three financial years out of which 8 offers closed below the offer price on listing date.• The Price/Earnings ratio based on diluted EPS for Fiscal 2021 for the Company at the upper end of the Price band is as high as 77.60 as compared to the average industry peer group PE ratio of 73.08 (excluding PE ratio of one industry outlier).• Weighted Average Return on Net Worth for Fiscals 2021, 2020 and 2019 is 35.0%.• Average Cost of acquisition of Equity Shares for the Selling Shareholder namely Singapore VII Topco III Pte. Ltd. Is ₹ 32.34 and the Offer Price at the upper end of the Price Band is ₹ 291 per Equity Share.

Bangalore, June 9, 2021: Sona BLW Precision Forgings Limited, one of India’s leading automotive technology companies, is primarily engaged in designing, manufacturing and supplying highly engineered, mission critical automotive systems and components to automotive OEMs. The bid/offer period in relation to its initial public offering of Equity Shares (the “Offer”) will open on Monday, June 14, 2021 and close on Wednesday, June 16, 2021. The price band for the Offer has been determined at Rs. 285 – Rs. 291 per Equity Share. The Company and the Selling Shareholder have, in consultation with the book running lead managers to the Offer (the “BRLMs”), considered participation by Anchor Investors, which participation shall be one Working Day prior to the bid/offer opening Date, i.e. Friday, June 11, 2021.

The total Offer size is up to Rs. 5,550 crores with a fresh issuance of equity shares, aggregating up to Rs.300 crores and an offer for sale of equity shares aggregating up to Rs. 5,250 crores, by the Selling Shareholder, namely, Singapore VII Topco III Pte. Ltd. The Company intends to utilize the proceeds from the fresh issue to repay/prepay approximately Rs. 241.12 crores of its identified borrowings, besides general corporate purposes.

The company is a leading supplier to the fast-growing global Electric Vehicle (EV) markets and derived 13.8% revenue from the Battery EV market and 26.7% from the Micro Hybrid / Hybrid market in FY21. Its global market share of BEV differential assemblies in calendar year 2020 was 8.7%. The company is among the top ten players globally in the differential bevel gear market and in the starter motor market on the basis of respective volumes supplied to its end segments in calendar year 2020 and has been gaining global market share across products. According to the Ricardo Report, it serves 6 of the top 10 global PV OEMs, 3 out of top 10 global CV OEMs and 7 out of top 8 global tractor OEMs by volumes. The company has strong R&D, engineering and technological capabilities in precision forging, mechanical and electrical systems, as well as base and application software development. It is diversified across geographies, products, vehicle segments and customers. According to the Crisil Report, the company has the highest operating EBITDA margin, PAT margin, ROCE and ROE in FY20 as compared to top 10 listed auto component manufacturers in India by market capitalization and has consistently delivered more than 26% EBITDA margin and more than 35% average ROE each year over FY19-21. Its operating income growth over FY16-20 has exceeded the average of the same peer set.

The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended, read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made in accordance with Regulation 6(2) of the SEBI ICDR Regulations, through the Book Building Process wherein not less than 75% of the Offer shall be available for allocation to qualified institutional buyers, not more than 15% of the Offer shall be available for allocation to non-institutional bidders and not more than 10% of the Offer shall be available for allocation to retail individual bidders.

Kotak Mahindra Capital Company Limited, Credit Suisse Securities (India) Private Limited, JM Financial Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited are the BRLMs to the Offer.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus dated June 7, 2021 (“RHP”) filed with the Registrar of Companies, NCT of Delhi and Haryana at New Delhi (“RoC”).
Disclaimers
SONA BLW PRECISION FORGINGS LIMITED is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public issue of its Equity Shares and has filed the RHP with the RoC and thereafter with Securities and Exchange Board of India (“SEBI”) and the Stock Exchanges. The RHP shall be available on the website of the SEBI at http://www.sebi.gov.in as well as on the websites of the book running lead managers, Kotak Mahindra Capital Company Limited, Credit Suisse Securities (India) Private Limited, JM Financial Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited at http://www.investmentbank.kotak.com, http://www.credit-suisse.com/in/en/investment-banking-apac/investment-banking-inindia/ipo.html, http://www.jmfl.com, http://www.jpmipl.com and http://www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, see “Risk Factors” beginning on page 26 of the RHP. The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with the applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) in the United States only to “qualified institutional buyers” (as defined in Rule 144Aunder the U.S. Securities Act) in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and (b) outside the United States in offshore transactions as defined in and in compliance with Regulation S and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering in the United States.

City Today News
9341997936

Muthoot Finance initiates a vaccination drive in Karnataka

Bangalore, May 2021: Muthoot Finance is India’s largest gold loan NBFC. The company has initiated a COVID-19 vaccination support project through its mobile laboratory Muthoot Snehasraya in association with Myvacc.in team that will provide vaccination drives in Karnataka. ‘Muthoot Snehasraya’ is a CSR initiative of Muthoot Finance Ltd, intended for prevention, early detection and awareness of Kidney related diseases and for supporting dialysis patients by financial aid.   MyVacc.in is a platform for vaccinations of children and adults at home, corporates at offices, communities and schools.

Muthoot Finance aims to help the underprivileged 45+ segment to get vaccinated and encourages vaccination to build a protective shield that will help in fighting against the second-wave of COVID-19. This initiative will be carried out free of cost.

Mr. George M Alexander Muthoot, Executive Director, Muthoot Finance said, “The core objective of Muthoot Finance Snehasraya project is to protect and get the underprivileged vaccinated for free. We will expand this vaccination project to other states in the upcoming months.”

Muthoot Finance is extending vaccination drives through Muthoot Snehasraya mobile laboratory with the help of Myvacc.in which will be providing COVID-19 vaccines at the doorstep across several areas in Karnataka.

City Today News
9341997936

Neuberg Diagnostics launches NCGM, its first Laboratory in the USA

~ Neuberg becomes the first lab chain of Indian origin to start direct operations in the USA with CLIA certified lab operations ~

~ Unites key collaborators under one umbrella for molecular and genomics based new generation testing ~

May 03, 2021: Neuberg Diagnostics, a global laboratory testing group, announced the start of its clinical laboratory operations in North Carolina in the United States of America (USA). The laboratory in North Carolina, known as NCGM, Inc. (Neuberg Centre for Genomic Medicine), will focus on genomic and molecular testing based on new generation sequencing techniques. It also runs an extensive network of labs in India, South Africa, and the UAE as well.

NCGM has introduced COVID-19 molecular testing to detect active SARS CoV-2 virus infections that is of immediate public health priority in North America, along with genome scale testing, such as Exome Sequencing, which is applicable across a variety of Rare Genetic Disease Testing (Inherited Diseases) from Newborn Screening to Oncology to Pediatric Care Setting.

Dr. GSK Velu, Chairman & Managing Director of Neuberg Diagnostics, said, “NCGM, USA will act as the laboratory and hub, aiding our operations in the North America. Through leveraging our collaborative efforts across our organization in India, South Africa, and UAE, and with our external partners, we aim to develop and provide the best-in-class affordable tests. As they are deployed, the accessibility and affordability of the tests will reduce disparity and benefit individuals across the board.”

Dr Sandip Shah, Executive Director Neuberg Diagnostics, said “NCGM, USA Sequencing services will be supported by in-house bioinformatics team and cutting-edge technologies which has been developed inhouse, and along with reputed partners. It will also support genetic research by leveraging our own extensive infrastructure in India, South Africa, and UAE.”

Dr. Andy Bhattacharjee, CEO, NCGM, USA, said, “The setup has comprehensive Genomic testing facility allowing large-scale clinical and research projects. With capacity to conduct more than 400 variety of tests, the center will conduct large-scale clinical diagnostics and genomics projects with greater sample volumes at an unprecedented depth and coverage of the genome. Currently we are offering Covid RT-PCR Testing Services at our NC Lab with home sample collection facilities in association with FexEx to help fight the pandemic in USA too. “

For more information about NCGM, USA, please visit – http://www.ncgm.us/ or write to us at contactncgm@neubergdiagnostics.com or call us at 252 371 1584

City Today News
9341997936

STAR INDIA LAUNCHES A NEW CAMPAIGN FOCUSSING ON THE REAL HD EXPERIENCE

STAR INDIA LAUNCHES A NEW CAMPAIGN FOCUSSING ON THE REAL HD EXPERIENCE
The TVC ‘SIRF DIKHAANE KE LIYE NAHI, DEKHNE MEIN BHI REAL HD EXPERIENCE’ will air across the Star India Network in 7 languages

Mumbai, April 30, 2021: Star India has launched a new network-wide television campaign (TVC) ‘SIRF DIKHAANE KE LIYE NAHI, DEKHNE MEIN BHI REAL ‘HD’ EXPERIENCE to build awareness among television lovers who, despite owning an HD TV and HD Set-Top Box (STB), continue to view their favourite Star channels in Standard Definition (SD).

Consumers often think that having an HD TV by itself provides the complete HD viewing experience, which is a myth the campaign aims to bust with a touch of humor. Based on the findings from a study conducted by Star India, only 25%* of consumers are aware of the fact that apart from having an HD TV and an HD Set-Top box they also need to subscribe to HD channels to get the complete HD viewing experience.
The campaign also highlights the features of Star HD channels such as wider picture, 5x sharper picture, and 5.1 Dolby surround sound that help make the viewing experience far more superior and immersive, ‘Taaki aapka HD TV sirf ‘dikhaane’ ke liye hee nahi, dekhne mein bhi Real HD experience de!’

Gurjeev Singh Kapoor, President – TV Distribution, India and International, Star And Disney India, said, “At Star India, we have always focused on providing an unparalleled entertainment experience and value to our viewers. There is a huge potential to further increase affinity towards our content with the large portfolio of 26 Star HD channels across genres and languages; with a strong live cricketing calendar this year and VIVO IPL 2021 just around the corner, we want consumers to experience the sheer delight and stadium-like feeling that our HD channels can provide. It is the right time for consumers to enhance their viewing experience with a Star HD channel subscription. Hence, this campaign is aimed at bridging the awareness gap and in helping consumers realize the relevance of recharging their Star HD channels.”

The campaign is driven by a well-conceptualized film that draws a parallel to people’s innate habit of keeping things in their homes for show value rather than using it for their intended purpose. Owning a fancy, flat-screen HD TV is something that elevates the social status of an individual, and the campaign cheekily nudges the consumer to elevate the value of their HD TV ‘Apne HD TV Ka Naam Roshan Kijiye’ by subscribing to Star HD channels. The campaign will also feature some of the most loved characters from the Star India Network endorsing the Real HD experience.

*study conducted amongst decision maker in TV channel packs subscription across 10,000+ Pay TV households in 2019, across 69 towns
**conditions apply

ANNEXURE
Star Network offers a holistic range of HD channels across genres & languages.

Channel Genre
Star Plus HD Hindi GEC
Star Bharat HD Hindi GEC
Star Gold HD Hindi Movies
Star Gold Select HD Hindi Movies
UTV HD Hindi Movies
Star Jalsha HD Bengali GEC
Jalsha Movies HD Bengali Movies
Vijay HD Tamil GEC
Star Suvarna HD Kannada GEC
Asianet HD Malayalam GEC
Star Movies HD English Movies
Star World HD English GEC
Star Movies Select HD English Movies
Disney International HD English GEC
Star Sports HD1 Sports
Star Sports HD2 Sports
Star Sports 1 HD Hindi Sports
Star Sports Select HD1 Sports
Star Sports Select HD2 Sports
Maa HD Telugu GEC
Maa Movies HD Telugu Movies
Star Pravah HD Marathi GEC
Baby TV HD Kids
National Geographic HD Infotainment
Nat Geo Wild HD Infotainment
Fox Life HD Infotainment

City Today News
9341997936

Made-in-India Virus Attenuation Device Shycocan launched in UAE to Help Curb Spread of Coronavirus

Invented by well-known scientist Dr. Rajah Vijay Kumar, the world’s first virus-attenuation device aims to get life and businesses back to normal amidst the pandemic

The device is proven to disable the Coronavirus and Influenza virus strains in indoor spaces, which carry the highest risk of transmission

Shycocan is scientifically evidenced to attenuate/neutralise 99.9% of both airborne and surface-borne Coronavirus family and Influenza family of viruses

Shycocan also works on all current and future variants and mutants of these viruses, ensuring a safe environment for both B2B and B2C

NEW DELHI / April 27, 2021: Shycocan, a breakthrough virus-attenuation device invented and manufactured in India, has been launched in the UAE at the International Conference of Pharmacy & Medicine (ICPM) held at Sharjah. This marks the Middle East debut of the product, the first of its kind in the world, that is seeing a robust demand from institutional buyers across the world in times of the raging Coronavirus pandemic.

The cylindrical device, Shycocan, is scientifically evidenced to neutralise and help curb the spread of the Coronavirus and Influenza family of viruses in indoor spaces with 99.9% efficacy, enabling schools, colleges, homes and businesses like hospitals, hotels, offices, restaurants, auditoriums, transportation, retail and airports get back to normal and serve the customers in a safe environment.

Remarkably, Shycocan also works on all current and future variants and mutants of these viruses, protecting people’s health and saving millions of hours of lost productivity.

Alok Sharma, Chief Executive Officer, Shycocan Corporation, said, “The world faced one of its biggest challenges with the pandemic, bringing us all to a standstill. More livelihoods than lives have been lost, in fact, close to a billion at the last count. Science, technology and innovation are going to play a big role in helping us reclaim our lives and work safely. We are delighted to launch the pathbreaking one- of-a-kind virus-attenuation device, the Shycocan, in the UAE in the hope of helping people bring lives and businesses back to normal. And we couldn’t have found a more credible and relevant platform than the prestigious ICPM to showcase our cutting-edge technology.”

Shycocan is distributed in the UAE for consumers and business customers by Redington Middle East LLC and Ibn Batuta Medicine & Medical Equipment Store LLC. It is one of the most thoroughly tested devices for both safety and efficacy. It neither uses nor emits radiation, chemicals, ozone or any toxic material. It is 100% safe for humans, animals and the environment. Additionally, it does not harm the bacterial ecosystem and microbes that thrive in the environment and are essential for our immunity.

Said the well-known scientist Dr. Rajah Vijay Kumarthe inventor of Shycocan,“Coronavirus-type outbreaks are occurring with faster intermittent frequencies. The COVID-19 strain is getting more infectious and deadlier with successive mutations in the last 17 years, underscoring the importance of a device like Shycocan. The biggest challenge of this virus is its infectivity or virulence. Breaking the chain of infectivity requires focused work on indoor environments because they carry the highest risk of transmission. In 2017, our campus in Bengaluru experienced many incidents of seasonal flu, compelling me to design, build and install the device which was later christened Shycocan. A year later, the incidence of seasonal flu was almost totally absent from the campus. When the COVID-19 pandemic struck, the device was sent for testing and regulatory compliances to global laboratories and found to be equally effective against it. It was overwhelming to realise that we had already created the world’s first technology to fight the pandemic long before imagining the possibility of such a crisis taking the entire world in its grip.”

Shycocan has widespread usage across market segments, including hospitals, clinics, schools, higher education institutions, banking sector, manufacturing and retail outlets, hospitality sector, government offices, real estate corporations and businesses. In addition, the company offers customised consultations, a one-year replacement warranty, strong support and service network across the UAE, and a post-installation audit.

A single device when mounted has an effective coverage area of 1,000 square feet (10,000 cubic feet). Multiple devices can be installed to cover a larger indoor space. The device has seen a robust demand from institutional buyers across the globe and is already in use in countries such as India, the US, Europe, Malaysia, Australia, New Zealand and South Africa, among others.

Dr Abdullah Al Kindi, Chairman & CEO, ICPM, said, “Mankind is facing one of the most challenging times – something that has impacted lives, livelihoods and businesses at a global scale. We as global citizens need the best of science, technology, social responsibility, and willpower to fight it – and triumph. ICPM was established with responsibility towards humanity and with healthcare as its foundation. It gives me immense pleasure to launch Shycocan on this platform. It is a product with innovative technology and the capability to bring businesses and lives back to normal.”

City Today News
9341997936